skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


The potential exhaustion of prescription drug user fees during the partial federal government shutdown could lead product sponsors or the US FDA itself to assert that certain application reviews should continue under the Anti-Deficiency Act’s emergency powers exception, two former agency officials said Jan. 24.

Howard Sklamberg, a partner at Akin Gump and former deputy commissioner for global regulatory operations and policy, and Rebecca Wood, a partner at Sidley Austin and former FDA chief counsel, said that if the shutdown lasts another month, they could see an attempt to invoke the agency’s emergency powers to either file a new drug application or complete its review of a pending application in the absence of user fee funding.

The two attorneys made their comments during a Food and Drug Law Institute webinar on the shutdown.

The Anti-Deficiency Act prohibits federal agencies from obligating or expending federal funds in advance or in excess of an appropriation, unless authorized by law or in emergencies involving the safety of human life or the protection of property.

FDA has been able to use carryover user fees to support the ongoing review of prescription and generic drug and biosimilar applications submitted before the Dec. 22 shutdown, and to continue policy work under the user fee programs. However, it has not been able to accept new applications that require payment of a fee and, consequently, it is burning through its user fee reserves.

“At what point would someone be able to craft an argument that they are trying to fill a therapeutic gap for a patient population that can’t wait? I think that may be where you see a whole new round of legal and policy interpretations that we just haven’t seen before.” – Sidley Austin’s Wood

FDA Commissioner Scott Gottlieb recently estimated that the remaining Prescription Drug User Fee Act funding would run out between Feb. 17 and Feb. 28, with “months” of funding remaining under the generic drug fee program. (Also see "US FDA Shuttering More Operations As User Fee Money Dwindles" - Pink Sheet, 23 Jan, 2019.)

The agency has not publicly said how much biosimilar user fee funding remains available. (Also see "US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress" - Pink Sheet, 22 Jan, 2019.)

For PDUFA products, “I think where it gets very unprecedented and potentially very interesting is what happens if this goes on for several weeks [and] we no longer have user fees available,” Wood said.

FDA is “not supposed to take any user fees. At what point would someone be able to craft an argument that they are trying to fill a therapeutic gap for a patient population that can’t wait? I think that may be where you see a whole new round of legal and policy interpretations that we just haven’t seen before,” Wood said.

Sklamberg outlined a scenario involving a breakthrough therapy-designated product in the absence of carryover user fees. “Maybe there’s a creative legal argument that that falls into one of the appropriations exceptions,” he said. “And then if you do that, how do you catch up with the user fees later?”

“I think if this ends up being a months-long shutdown, the agency is probably going to have to deal with that,” Sklamberg said. “You can’t have the drug and medical device approval system stop for months and months without it having an effect on patients.”

Drug Reviews Not Entirely Protected

Both attorneys cautioned that even though medical product reviews are continuing for the time being with carryover fees, such applications are not immune to the shutdown’s effects.

“It really is one FDA,” Wood said. “The agency is very integrated, and it’s a place that really focuses on bringing the right expertise to the table.”

“It is not uncommon, even if you think you have a pathway that should be covered because of user fees, that it would raise policy questions or scientific questions or legal questions that cross more into areas where people may not be sitting at their desks as they normally would and available or consultation,” she said.

“The lines are sometimes difficult to draw” between user fee work and activities that are not allowed to continue during a shutdown, Sklamberg said, noting that policy issues can cut across product centers and offices.

Consequently, figuring out what work can proceed, and by whom, is a constant challenge.

“FDA has a very good accounting system for accounting for its user fees, for tracking things, making sure everything is in the right bucket,” Sklamberg said. “But it’s not set up to be a law firm where people bill to the sixth minute.”

“It is a very big challenge for people just running the place to say you can work on this and this, but not the other thing.” – Akin Gump’s Sklamberg

“It is a very big challenge for people just running the place to say you can work on this and this, but not the other thing,” Sklamberg said. “That makes the work overall just less efficient.”

“Even the folks who are working on user fee projects … have an added burden of this accounting system [and] consulting with the lawyers about what they do,” he said. “It makes their job harder.”

FDA and product center leaders are constantly recalibrating the agency’s resources and activities as the shutdown grows longer, Wood said.

“The lawyers in [the Office of Chief Counsel] are probably quite busy right now fielding those questions and looking at precedent and looking at the legal justifications,” she said.

Employee Morale And Retention Will Take A Hit

Both former FDAers expressed deep concern about the shutdown’s potential impact on FDA employee morale and the agency’s recruiting and retention efforts.

Normal training and professional development activities tend to go by the wayside for a period of time when there is a shutdown, Wood said.

Sklamberg noted that many agency employees are eligible for retirement. He’s heard reports of some staff saying, “'To hell with this. I’m done.' And you’re going to lose some of those.”

“There also are a lot of people doing a lot of very important work who are not paid very well, and this is going to have an effect, I think, on their desire to have a long-term career, at least of some of them, which would be an unbelievable loss,” he said.


Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Medtech Insight: global medical technology news & analysis

    UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

    BSI tackles Brexit issues head-on with aim to allay fears and bring clarity while UK regulator, MHRA, remains reticent to do so. Its messages are relevant for all doing business in the UK

    Topics Brexit


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: